Sentences with phrase «tumors samples for»

The latter, presented by Eric Lander of the Broad Institute in Cambridge, Massachusetts, would systematically sequence tumor samples for mutations involved in cancer to speed up the search for new drugs and diagnostics.

Cells were extracted from the biopsy of her tumor sample for use in research without her knowledge or consent.

More than 150 cancer researchers have divvied up the work of sequencing about 500 tumor samples for each of some 20 cancer types (10,000 samples in total) at a cost of more than $ 375 million.

The idea is to sequence 10,000 tumor samples for each of several common cancers, such as breast and prostate.

Not exact matches

Interest in liquid biopsy has escalated in recent years due to the minimally invasive sampling method, potential to overcome the challenges of tumor heterogeneity, and the potential for longitudinal monitoring of tumor burden through serial sampling.

For example, TCGA, with genomic data on 33 tumor types taken from samples from 11,000 patients, is finishing 2018 by publishing a series of papers and holding a symposium.

While the latter has a reputation for being hard to isolate, she explains that even degraded RNA generally contains enough intact sequence to analyze — provided investigators can detect the scarce tumor signals against the immense background of other RNA molecules in a sample.

«The minimum sample volume required is only 1 µL for analysis of 92 proteins, which has been proven to be a great advantage for applications with limited sample volumes, such as pediatric applications, fine - needle biopsies, and tumor microbiopsies,» he says.

For investigators studying circulating tumor cells, the next step after sampling is to isolate the desired cells as quickly and gently as possible.

«Circulating tumor cells have the advantage that they are... intact living cells,» says Michael Kazinski, senior director and head of global product management for sample technologies at Qiagen in Hilden, Germany.

These tumor samples consistently tied to worse outcomes in children, suggesting a critical marker for predicting prognosis.

In order to enable a spatially precise sampling, the tumor areas in the PET and CT data for the examination are defined and transferred to a machine.

An index ranging from 0 to 1 was created for each tumor sample.

Plasma samples of patients with NSCLC is a less invasive method and has been used as surrogate tumor tissues for detecting genetic alterations.

A total of 67 biochemical features discriminated cancer from benign tumors in these samples, but only four specific metabolites could be considered as biomarkers for cancer: creatinine riboside, tryptophan, Nε, Nε, Nε - trimethyllysine, and 3 - methylhistidine.

The authors acknowledge that «tumor tissue should be considered the preferred sample type when available, however, our encouraging results suggest that a single plasma - derived ctDNA sample may be considered appropriate for assessment of EGFR mutation status when tumor tissue is unavailable or exhausted.»

The researchers next will turn to analyzing the presence of myoferlin in samples from numerous human tumor types available in an Ohio State tissue bank, which will allow them to compare protein levels in tumors to clinical outcomes for the patients who provided the samples.

For the study, researchers investigated tissue samples from 297 people with brain tumors.

The minimally invasive test could reduce the need for the sometimes painful and risky procedures involved in sampling tumors, particularly those that reside deep within the body.

They analyzed bacterial DNA found in breast tissue samples from 58 women who were undergoing lumpectomies or mastectomies for either benign or cancerous tumors, as well as from 23 healthy women who had undergone breast reductions or enhancements.

Samples of the tumor are excised, examined under a microscope and, often, analyzed to pinpoint the genetic mutations responsible for the malignancy.

Unlike other solid tumors, there has been limited progress in understanding the contribution of genetic risk factors to the development of uveal melanoma, researchers say, primarily due to the absence of comprehensive genetic data from patients as the large sample cohorts for this rare cancer type have not been available for research.

«With liquid biopsies, we don't have to wait for tumor growth to get a DNA sample,» says Dr. Vasmatzis.

«Being able to safely take tissue samples will also allow us to test for specific tumor sub-types and better decide the most appropriate treatment for each individual patient,» added Dr Booton.

For example, cancer cells floated above denser blood cells, which could allow clinicians to spot rare circulating tumor cells in a patient sample.

The role of rebiopsy and repeat analysis in the setting of post-treatment relapse, along with testing of blood samples for mutations in circulating tumor cells, cell free tumor DNA, or exosomes will be considered.

Analyzing the poly - G profiles of primary and metastatic colon cancer samples from 22 patients revealed that how the primary and metastatic tumors related to each other was different for each patient.

Answering important clinical questions — such as whether genetic diversity is a risk factor for aggressive tumor development or how it relates to treatment resistance — requires analyzing samples from many patients with different types of cancer.

NYGC computational biologists and members of the Simon Laboratory at The Rockefeller University discussed the possibility of using a series of computer algorithms to search for sequence differences between the tumor samples and samples of healthy liver tissue.

To confirm that the missing mutations were important for generating an immune response, the researchers cultured a subset of the neoantigen protein fragments containing the tumor mutations with immune cells taken from three patients» blood samples.

«Our findings show that high - intensity circulating tumor DNA sequencing is possible and may provide invaluable information for clinical decision - making, potentially without any need for tumor tissue samples,» said lead study author Pedram Razavi, MD, PhD, a medical oncologist and instructor in medicine at Memorial Sloan Kettering Cancer Center (MSK) in New York, NY.

To search for other characteristics of ccRCC tumors that influences immunotherapy response or resistance, the researchers used whole - exome DNA sequencing to analyze tumor samples from 35 patients treated in a clinical trial with the checkpoint blocker nivolumab (Opdivo).

For 124 evaluable patients for concordance analysis, researchers compared genetic changes in the tumors to those in circulating tumor DNA from the blood samplFor 124 evaluable patients for concordance analysis, researchers compared genetic changes in the tumors to those in circulating tumor DNA from the blood samplfor concordance analysis, researchers compared genetic changes in the tumors to those in circulating tumor DNA from the blood samples.

For this study the authors studied tumor samples from 111 patients treated at the Instituto Nacional de Enfermedades Neoplásicas (INEN), in Lima, Perú.

To explore this idea, Hopkins oncologists Dung Le, Luis Diaz, and others looked for mismatch repair mutations in tumor samples from patients with advanced colon cancer and other cancer types whose tumors had stopped responding to other treatments.

«This broad implication is in contrast to a more traditional vaccine - based approach, which requires a specialist to surgically remove tumor samples from a patient's body then create a personalized vaccine approach for one specific patient.»

Searching for T cells that had infiltrated the tumors, they collected as many as 50 T cell samples from a single tumor; next, the team tested each batch of T cells against other tumor samples from the same patient.

Fifteen teams analyzed nearly 500 patients» tumors for genetic aberrations and sequenced the protein - coding DNA of 316 samples — by far the largest cancer sequencing effort to date.

To test their hunch, the researchers isolated microvesicles from 30 frozen tumor samples and looked for mRNA from a particular growth receptor unique to glioblastomas.

Rather than wait for tumor biopsy samples to become available, scientists captured «cell - free» DNA shed into the bloodstream by the tumor cells.

Applying this tool to the six patients» tumor samples yielded dozens of unique neoantigens for each patient's personal vaccine.

In order to test whether the method is suitable for use in clinical routine diagnostics, the scientists analyzed more than 1,100 additional tumor samples.

«Based on our findings, the next phase will be to measure exosomes and exomeres in plasma samples to help predict organs that may be targeted for metastasis during tumor progression,» said Dr. Lyden.

The test, called ProsignaTM and manufactured by NanoString Technologies, comes with a machine and kit, so patients» tumor samples do not have to be sent to a single laboratory for analysis.

The company has labs around the world, from London to Israel to Singapore, to reduce the amount of time a given tumor sample spends on a plane, for example.

The researchers took healthy tissue and tumor samples from mice, and trained the nanoparticle - GFP sensors to recognize the bad cells, and for the GFP to fluoresce in the presence of metastatic tissues.

The scientists extensively studied 28 tumor samples from children with medulloblastoma, surveying each tumor for details about how its genes are turned on and off.

To that end, Sharma gave an overview of MD Anderson's efforts to comprehensively characterize the activity of the immune cells in the patients they treat, and they've already analyzed over 42,000 tumor tissue samples, from both before and after treatment, looking for clues regarding how treatment outcomes relate to immune cell infiltration into tumors.

Guided by a camera and the ultrasound probe, Waxman carefully positioned the endoscope over the tumor and passed a fine needle into the pancreatic lesion to sample tissue cells for biopsy.

Blood and tumor samples were also taken for immune cell response analyses.